欧林生物11月14日获融资买入3169.08万元，融资余额3.31亿元

Core Insights - On November 14, Oulin Bio's stock rose by 4.29%, with a trading volume of 271 million yuan [1] - The company reported a net financing outflow of 913,200 yuan on the same day, with a total financing and securities balance of 331 million yuan [1] - Oulin Bio's main business involves the research, production, and sales of human vaccines, with significant revenue contributions from various vaccine products [1] Financing and Trading Data - On November 14, Oulin Bio had a financing buy-in of 31.69 million yuan, while the financing balance reached 331 million yuan, accounting for 3.29% of the circulating market value [1] - The financing balance is above the 90th percentile level over the past year, indicating a high level of financing activity [1] - No shares were sold or repaid in the securities lending market on the same day, with a balance of 0 yuan [1] Financial Performance - As of September 30, Oulin Bio reported a total revenue of 507 million yuan for the first nine months of 2025, representing a year-on-year growth of 31.11% [2] - The net profit attributable to shareholders reached 47.48 million yuan, showing a significant increase of 1079.36% compared to the previous period [2] Shareholder and Dividend Information - Since its A-share listing, Oulin Bio has distributed a total of 15.43 million yuan in dividends [3] - As of September 30, 2025, the number of shareholders increased to 10,200, a rise of 56.42%, while the average circulating shares per person decreased by 36.07% to 39,746 shares [2][3] - Notable institutional holdings include XQH Run Mixed A and XQH Yi Mixed A, with stable shareholding numbers [3]